SRPT Sarepta Therapeutics Operating Profitability

SRPT (Sarepta Therapeutics) - company brandmark

The operating margin on GURU.Markets demonstrates the real business efficiency of Sarepta Therapeutics, Inc. (SRPT), where -0.40 is the current value of the indicator. The stability of Sarepta Therapeutics, Inc. (SRPT) is based on its independence from macroeconomic factors, creating a defensive asset. High margins are ensured by a monopoly on unique gene therapy with patent protection, while the company's flexibility is maintained by outsourcing production and trials to external contractors.

SRPT: Sarepta Therapeutics Operating Return on Sales 07/04/2022 - 11/20/2026

Financial and market metric breakdowns for Sarepta Therapeutics, Inc. (SRPT)

- share price and consensus valuation forecast:
Initial company analysis:Sarepta Corp, SRPT
Brand item of Sarepta Corp

Investors require an objective tool to measure the efficiency of the issuer's resource management. This metric reflects the share of operating profit in revenue before financial expenses, allowing for an assessment of the business's fundamental stability through the monitoring of operating margin. Growth in this metric may be driven by one-time asset revaluations in 10-K filings. For Sarepta Therapeutics, Inc. (SRPT), this reflects the balance between gene therapy costs and compliance with strict ESG disposal standards. Effective energy saving in laboratories directly optimizes operating expenses.

Analysis of competing companies

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Ultragenyx Pharma (RARE) - Operating Sales Margin|beamtx.com (BEAM) - Operating Profitability|TWST: Operating Profit Ratio|TXG (10xgenomics.com) - Operating Margin|NTLA (Intellia Therapeutics, Inc.) - Operating Profit Ratio|Operating Profitability Stoke Corp (STOK)|Profitability of Operations BioLife|Operating Margin WVE (Wave Life Sciences Ltd)|MAZE: Return on Sales by Operating Profit|Sionna Therapeutics, Inc. - Operating Margin|Operating Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Operating Sales Margin|QURE - Profitability of Operations|MGTX (MeiraGTx Corp) - Operating Margin|Operating Return on Sales REGENXBIO Inc. RGNX|Operating Profitability Solid Biosciences (SLDB)|Ocugen Corp - Return on Sales by Operating Profit|Operating Profitability Pacific Biosciences PACB|Operating Profit Ratio BNTC (Benitec)|Design Corp - Operating Margin|Rocket Pharmaceuticals - Operating Profit Ratio|Return on Sales by Operating Profit 4D Molecular Therapeutics, Inc.|Operating Return on Sales Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Operating Margin|Operating Return on Sales Editas EDIT|Operating Margin SLN|ProQR Therapeutics - Return on Sales by Operating Profit|Operating Margin CDXS (Codexis, Inc.)|SGMO: Return on Sales by Operating Profit|Nautilus Biotechnology - Operating Margin|Operating Profit Rate MGX (Metagenomi, Inc)|DTIL: Operating Margin|GBIO: Operating Profit Ratio|Operating Profitability Boundless Bio Inc.|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability